Table 4

CONSORT quality assessment of RCT articles on maintenance treatment in AML

ReferenceReport domains
Title/abstractIntroductionMethodsResultsDiscussionOther information
12345678910111213141516171819202122232425
abababababababababababab
22 
20 
11 
13 
16 
15 
10 
14 
17 
ReferenceReport domains
Title/abstractIntroductionMethodsResultsDiscussionOther information
12345678910111213141516171819202122232425
abababababababababababab
22 
20 
11 
13 
16 
15 
10 
14 
17 

Items not applicable to each study as well as those assessed adequate are coded 1. Details of scoring are provided in Moher et al. The designation of 0 corresponds to the absence and 1 corresponds to the presence of a potential deficiency. The following score/domain correspondence was used: 1a, identification as RCT in the title; 1b, structured summary of trial design, methods, results, and conclusions; 2a, background and rationale; 2b, objectives and/or hypotheses; 3a, design including allocation ratio; 3b, important changes to methods after trial commencement; 4a, eligibility criteria; 4b, settings and locations; 5, interventions; 6a, prespecified outcomes; 6b, changes to outcomes after trial commencement; 7a, sample size determination; 7b, interim analyses, if applicable; 8a, random allocation sequence generation; 8b, randomization type; 9, allocation concealment; 10, who generated the random allocation sequence, who enrolled participants, and who assigned them to interventions; 11a, blinding; 11b, similarity of interventions, if applicable; 12a, statistical methods for primary and secondary end points; 12b, methods for additional analyses; 13a, flow diagram or equivalent; 13b, losses and/or exclusions after randomization, with reasons; 14a, recruitment and/or follow-up dates; 14b, why the trial ended or was stopped, if applicable; 15, baseline demographics and clinical characteristics of each group; 16, number analyzed in each group and whether analysis was intention to treat; 17a, results in each group, effect size and its precision for each outcome; 17b, absolute and relative effect size recommended for binary outcomes; recommended; 18, results of other analyses; 19, harms and unintended effects in each group; 20, limitations, including biases and imprecisions; 21, generalizability; 22, consistency of interpretation and results, balancing benefits and harms, other relevant evidence; 23, registration number and name of registry; 24, where the full protocol can be accessed, if available; 25, funding and its role.

Close Modal

or Create an Account

Close Modal
Close Modal